Kezar Life Sciences, which is developing selective immunoproteasome inhibitors to treat autoimmune diseases, raised $75 million in a slightly upsized IPO by offering 5 million shares at $15, the midpoint of the $14 to $16 range. The company originally planned to offer 4.7 million shares. Insiders intended to buy $30 million on the IPO (40% of the deal). Kezar Life Sciences plans to list on the Nasdaq under the symbol KZR. Jefferies, Cowen & Company, Wells Fargo Securities and William Blair acted as lead managers on the deal.
